NMRA (Neumora Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
Neumora Therapeutics, Inc. Common Stock (NMRA) is a publicly traded Healthcare sector company. As of May 21, 2026, NMRA trades at $1.78 with a market cap of $327.95M and a P/E ratio of -1.18. NMRA moved +3.59% today. Year to date, NMRA is +5.20%; over the trailing twelve months it is +135.71%. Its 52-week range spans $0.61 to $17.19. Analyst consensus is strong buy with an average price target of $9.33. Rallies surfaces NMRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns NMRA stock?
Hedge funds tracked by Rallies that own NMRA include Orbimed Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Neumora Therapeutics, Inc. Common Stock.
NMRA Key Metrics
Key financial metrics for NMRA
Metric
Value
Price
$1.78
Market Cap
$327.95M
P/E Ratio
-1.18
EPS
$-1.45
Dividend Yield
0.00%
52-Week High
$17.19
52-Week Low
$0.61
Volume
10
Avg Volume
0
Revenue (TTM)
$0
Net Income
$-236.93M
Gross Margin
0.00%
Top Hedge Funds Holding NMRA
Orbimed Advisors holds 805.00K shares of NMRA, changed -46.33% as of Dec 31, 2024.
Hedge funds tracked by Rallies that own NMRA include Orbimed Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Neumora Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for NMRA?
Yes. Rallies tracks hedge fund and 13F ownership data for NMRA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is NMRA research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NMRA. It does not provide personalized investment advice.
